The Types segment classifies the market by molecular architecture and pharmacokinetic profile, separating unfractionated heparin (UFH), low‑molecular‑weight heparin (LMWH), and synthetic heparinoids. UFH, a heterogeneous polysaccharide mixture, remains the largest revenue generator, representing roughly 55 % of the market because of its rapid onset, reversibility with protamine, and entrenched use in high‑risk surgical settings. LMWHs—such as enoxaparin, dalteparin and tinzaparin—capture about 35 % of sales; their longer half‑life, predictable dose‑response and outpatient convenience drive adoption in prophylactic protocols for orthopedic and oncology patients. Synthetic heparinoids, including fondaparinux and idraparinux, occupy the remaining 10 % and are expanding in niche indications where antithrombin‑III independence offers a safety advantage. Each type’s share reflects distinct cost structures, dosing frequencies, and regulatory pathways, which collectively shape the overall Heparin Anticoagulant Drugs market size. The taxonomy underscores how shifting clinical preferences toward LMWHs and selective heparinoids could re‑balance the revenue mix over the forecast horizon. In addition, pricing pressure on UFH from generic competition is moderating its growth, while the incremental cost of LMWHs is justified by reduced hospital stay and lower monitoring requirements.
